Allos1000, A1K

A1K : Atopic dermatitis Drug

Atopic dermatitis is a chronic inflammatory skin disease with itching and dry skin as its main symptoms. It usually starts in infancy and, as it grows, it is accompanied by allergic diseases such as allergic rhinitis and asthma. The number of patients with atopic dermatitis is increasing worldwide. Until the 1970s, it was reported that about 3% of children under the age of 6 suffered from atopy, but recently, it is estimated that 20% of children and 1-3% of adults suffer from atopy.

Atopic dermatitis is a chronic disease that improves during treatment and relapses when treatment is stopped. Depending on the patient, symptoms improve and worsen for several months to several decades, so the treatment period for patients is long and side effects may appear. Atopic dermatitis, which has a complex pathogenesis, has no clear cause treatment yet, so non-specific immunosuppressants such as steroids and calcineurin inhibitors are mainly prescribed, but the side effects are significant, so there is a high need for the development of new drugs.

Allos1000 (A1K) is a treatment that simultaneously relieves inflammation and itching caused by atopic dermatitis by improving damaged skin barrier. It is being developed as a topical preparation to be applied to the skin as a peptide drug.